GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K
inhibitor GDC-0941 when given with the chemotherapy cisplatin. This study will also examine
how well the combination of GDC-0941 and cisplatin work in treating patients with androgen
receptor negative triple negative metastatic breast cancer. Patients will be randomized to
receive cisplatin alone or cisplatin with GDC-0941 in the phase II portion. Those receiving
cisplatin alone can receive GDC-0941 upon progression of their disease. Cisplatin is a
chemotherapy which has been shown to be effective in treating triple negative breast cancer.
Preclinical studies show that adding a PI3K inhibitor such as GDC-0941 to cisplatin may be a
more effective treatment for breast cancer.